Monitor for upcoming updates on partnering deals for AD04, which could provide non-dilutive funding and validation of the drug's commercial potential. The compliance resolution removes an overhang but does not change the fundamental development-stage biotech risk profile.
Price Chart
Executive Summary
Adial Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement after its stock closed above $1.00 for 10 consecutive business days. The company also highlighted ongoing advanced partnering discussions for its lead drug candidate AD04 as it advances toward Phase 3 trials.
Key Facts
- Nasdaq confirmed compliance with Listing Rule 5550(a)(2) due to 10 consecutive days of closing bid price at or above $1.00 (Feb 6-20, 2026)
- The delisting threat has been resolved and the matter is now closed per Nasdaq
- Company emphasized advanced strategic partnering discussions for AD04's development and commercialization
- AD04 is in planning for a new Phase 3 trial for Alcohol Use Disorder in genetically targeted patients
- Recent ONWARD Phase 3 trial showed promising results in reducing drinking with no major safety concerns
Financial Impact
No direct financial impact reported; resolution of potential delisting risk
Risk Factors
- Clinical trial risk for AD04 in upcoming Phase 3 program
- Dependence on successful partnership formation for funding future development
- Continued financial and operational risks typical of clinical-stage biopharmaceutical companies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-019639 |
| Document: ea027811401ex99-1_adial.htm | 0001213900-26-019639 |
| Document: 0001213900-26-019639-index-headers.html | 0001213900-26-019639 |
| Document: 0001213900-26-019639-index.html | 0001213900-26-019639 |
| Document: 0001213900-26-019639.txt | 0001213900-26-019639 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 10-Q/A | $4.11 | awaiting T+60 | — | $3.68 (+10.46%) |
Oct 20, 2026 6d ago | S-3/A | $4.11 | awaiting T+60 | — | $3.68 (+10.46%) |
Oct 16, 2026 10d ago | DEFA14A | $3.62 | awaiting T+60 | — | $3.68 (−1.66%) |
Oct 16, 2026 10d ago | 8-K | $3.62 | awaiting T+60 | — | $3.68 (−1.66%) |
Sep 30, 2026 26d ago | Press Release | $4.13 | awaiting T+60 | — | $3.68 (−10.90%) |
Sep 18, 2026 5w ago | DEFA14A | $4.40 | awaiting T+60 | — | $3.68 (−16.36%) |
Sep 18, 2026 5w ago | 8-K | $4.40 | awaiting T+60 | — | $3.68 (−16.36%) |
Sep 16, 2026 5w ago | DEFA14A | $5.21 | awaiting T+60 | — | $3.68 (−29.37%) |
Sep 16, 2026 5w ago | 8-K | $5.21 | awaiting T+60 | — | $3.68 (−29.37%) |
Aug 17, 2026 10w ago | 8-K | $4.99 | awaiting T+60 | — | $3.68 (−26.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers